The shareholders' meeting, as the supreme management body of the HZI, meets at least once a year, takes the most important directional decisions, appoints the two managing directors and decides on their discharge. Representatives of the shareholders - together with experts from universities, clinics, industry, other research centres and the HZI itself - form the supervisory board. The HZI Supervisory Board meets twice a year, supervises the legality, expediency and economic efficiency of the management and decides on important research policy and financial matters of the company. The Scientific Committee provides the Supervisory Board with expert advice. The Centre's middle management consists of the heads of the scientific departments, the administrative units and the staff units.
Markus Cornberg is a university professor of infectious diseases with a focus on hepatology and deputy director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School. His clinical focus is the treatment of patients with infectious liver diseases. In 2019, he was also appointed Clinical Director of the HZI and Director of the Centre for Individualised Infection Medicine (CiiM).
Prof. Cornberg has been involved as a responsible physician in numerous clinical trials investigating new drugs for the treatment of viral infections of the liver. He was the first scientific secretary of the Competence Network Hepatitis (HepNet) in 2002. In February 2005, he took over the management of HepNet and, since 2007, the medical management of the German Liver Foundation. Since 2007 he has been involved in the preparation and revision of the German guidelines on viral hepatitis B, C and D. Since 2007, Prof. Cornberg has coordinated the preparation of the S3 guideline on the management of hepatitis B virus infection. In 2012, he was the German representative for the preparation of the European Hepatitis B Guideline. From 2017 to 2020, Prof. Cornberg was a member of the Governing Board of the European Association for the Study of the Liver (EASL). His basic science research focuses on the importance of cellular immune responses for disease progression and treatment response in patients with viral hepatitis. Prof. Cornberg has published more than 300 original scientific papers as well as review and book chapters.